Icon CE  CardioExcyte 96 publication in Journal of Laboratory Automation (2015)

Authors: 
Doerr L., Thomas U., Guinot D.R., Bot C.T., Stoelzle-Feix S., Beckler M., George M., Fertig N.

Journal: 
J Lab Autom (2015) 20(2):175–188


Abstract: 

The need for predictive, in vitro cardiac safety screening drives further development of automated, high-throughput–compatible drug evaluation based on cardiac cell preparations. Recently, pluripotent stem cells are evaluated as a new, more predictive model for cardiovascular risk assessment pertaining to in vitro assays. We present a new screening platform, the CardioExcyte 96, a hybrid instrument that combines impedance (cell contractility) with extracellular field potential (EFP) recordings. The electrophysiological measurements are noninvasive, label free and have a temporal resolution of 1 ms. This hybrid technology addresses the lack of easy-to-use high-throughput screening for in vitro assays and permits the reliable investigation of short- and long-term pharmacological effects. Several models of cardiomyocyte preparations were successfully validated for use with the CardioExcyte 96. Furthermore, the pharmacological effects of a number of reference compounds were evaluated. Compound effects on cell monolayers of human-induced pluripotent stem cell–derived cardiomyocytes are evaluated using a quasi-simultaneous hybrid recording mode that combines impedance and EFP readouts. A specialized software package for rapid data handling and real-time analysis was developed, which allows for comprehensive investigation of the cellular beat signal. Combining impedance readouts of cell contractility and EFP (microelectrode array–like) recordings, the system opens up new possibilities in the field of in vitro cardiac safety assessment.


Download here

Back to Overview

Contact Us

Please type your full name.
Invalid email address.
Invalid Input
Invalid Input
Nanion Technologies GmbH

Ganghoferstr. 70A
D-80339 Munich - Germany
info@nanion.de